Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 11/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15867660 | 0.79 | MAPT (0.40) | HTR5AJAK2MAPTKDM4EGAA | |
| SCHEMBL15867655 | 0.75 | HTR5A (0.32) | HTR5AJAK2 | |
| SCHEMBL8931368 | 0.70 | HTR5A (0.36) | HTR5AMAPTGAAIDO1EGFR | |
| SCHEMBL17531860 | 0.68 | ALDH1A1 (0.43) | MAPTIDO1 | |
| SCHEMBL8931370 | 0.67 | HTR2A (0.40) | GAA | |
| SCHEMBL15867658 | 0.67 | TSHR (0.36) | HTR5A | |
| SCHEMBL30660843 | 0.66 | HTR5A (0.39) | HTR5AMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL5968223 | 0.66 | JAK2 (0.35) | JAK2 | |
| SCHEMBL8119431 | 0.64 | HTR5A (0.34) | HTR5AMAPTKDM4EGAAIDO1 | |
| SCHEMBL15867656 | 0.64 | HTR5A (0.31) | HTR5AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212209-B2 | Screening methods for spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MYOF, MTPN | HTR5A 3793/4885JAK2 4656/4885MAPT 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.